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Abstract
Background and Aim—Circulating adiponectin is known to correlate negatively with insulin
resistance in patients with obesity and diabetes. The aim of this study was to assess the effect of
gastric bypass (GB) surgery on adiponectin gene expression in subcutaneous and omental adipose
tissues.
Methods—Adipose tissues and plasma were obtained from 25 subjects undergoing GB surgery,
15 non-obese subjects, and 12 subjects after GB surgery. Real-time quantitative reverse
transcription polymerase chain reaction (RT-PCR) was used for analysis of the adipose tissues.
Adiponectin expression was normalized for GAPDH and expressed as percentage of subject-
matched subcutaneous expression which was given an arbitrary value of 100%. Insulin resistance
was assessed by the homeostatic model assessment (HOMA). Circulating adiponectin was assayed
by ELISA.
Results—Omental adiponectin gene expression was 5-fold higher in subjects after GB when
compared with age matched morbidly obese subjects before GB (P<0.01). There were not
statistical differences in omental adiponectin gene expression observed in subjects after GB and
age matched non-obese subjects. For the entire cohort of subjects, there was a significant negative
correlation between omental adiponectin expression and insulin resistance expressed by HOMA
values (r=−0.62, P<0.001). Circulating adiponectin was significantly lower (p<0.05) in the obese
group than in the non-obese and post-GB groups.
Conclusion—Omental adiponectin gene expression significantly increase after GB surgery
reaching levels equal to age matched non-obese subjects. Omental adiponectin expression has a
significant negative correlation with the insulin resistance status.
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INTRODUCTION
Large epidemiologic studies reveal that the risk for insulin resistance increases from the very
lean to the very obese [1]. However, not all types of obesity are associated with increased
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risk of metabolic and cardiovascular complications [2]. Individuals with peripheral fat
distribution in the gluteo-femoral regions are less prone to develop type 2 diabetes (T2DM)
and cardiovascular disease (CVD) than individuals with abdominal fat distribution [2].
Furthermore, the amount of intra-abdominal fat strongly correlates with insulin resistance
and can account for most of the variability in insulin sensitivity in the obese population [3].
Abdominal visceral fat is an important link between the many facets of the metabolic
syndrome (i.e. glucose intolerance, hyperinsulinemia and hypertriglyceridemia) and other
features such as hypertension and altered high-density lipoprotein (HDL) and very-low-
density lipoprotein (VLDL) levels [4, 5]. The “portal paradigm”, built up from several
clinical observations, stated that the complications of obesity are mainly attributable to
increases in visceral adipose tissue mass [6]. As compared with subcutaneous adipocytes,
visceral adipocytes have high basal lipolysis, are highly sensitive to catecholamines and are
poorly sensitive to insulin [7]. These traits are magnified when visceral adipocytes become
hypertrophic [8]. As a result, enlarged visceral fat stores tend to flood the portal circulation
with free fatty acids (FFA) at metabolically inappropriate times when FFA are unlikely to be
oxidized, thus exposing tissues to excessive FFA levels and giving rise to insulin resistance
syndrome and beta-cell failure [9]. However the central and sole role of FFA in the
pathogenesis of insulin resistance has been challenged by the discovery of leptin, the first
peptide hormone demonstrated to be secreted by adipose tissue, and by the discovery of the
protein now generally known as adiponectin, produced almost exclusively by adipocytes
[10]. Since that time it has been recognized that adipose tissue is the site of expression of a
large number of peptides that relate to metabolic regulation, including known cytokines such
as TNF-α and IL-6 and known proteins with other functions such as angiotensinogen
(potentially involved in raising blood pressure), plasminogen activator inhibitor-1
(potentially involved in generation of a prothrombotic state) and some of the acute-phase
proteins that are markers of inflammation [11]. These proteins secreted by adipose tissue are
now generally known as adipokines. Adipose gene expression of TNF-α and PAI-1 are
elevated with obesity [12–14], while the expression levels of adiponectin are lower [15, 16].
Reduction in visceral fat mass correlates with decreases in the serum levels of many of these
pro-inflammatory adipokines and increase of adiponectin [17]. Therefore, the aim of this
study was to test the hypothesis that significant and sustained weight loss, induced by gastric
bypass (GB) surgery, increase adiponectin gene expression in the omental fat depot.
METHODS
The study approved by the local Institutional Review Board was conducted at the Vanderbilt
University Medical Center. Participants were enrolled among subjects status post GB
surgery (with a least 12 months follow up) undergoing an elective abdominal surgical
procedure (e.g. cholecystectomy, abdominal wall hernia repair, and/or abdominoplasty),
subjects with class II and III obesity undergoing GB surgery, and non-obese (BMI: 20–29)
control subjects requiring an elective abdominal surgery.
Obese and normal weight controls were selected to match age distribution of the post-GB
group. The study employed the following exclusion criteria: diagnosis of neoplastic disease,
inflammatory bowel disease, acute cholecystitis, and pregnancy.
During the surgical procedure, immediately after entering the abdominal cavity, two <0.5-
cm3 biopsies of abdominal subcutaneous and intra-abdominal omental fat tissue were
obtained. The tissue samples were washed in PBS solution and then soaked in RNAlater
preservative solution (Qiagen, Courtaboeuf, France) and stored at −80°C until analysis. All
the samples were stored in the same −80°C freezer and then analyzed together. Total RNA
was extracted from the adipose tissue biopsies using the RNeasy total RNA Mini kit
(Qiagen). The integrity of total RNA was checked by electrophoresis through an agarose gel.
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Adiponectin gene expression was studied by quantitative, real-time RT-PCR using the
specific protocol for the iCycler iQ Detection System (BioRad, Hercules, CA, USA) with
SYBR green fluorophore. Reactions were performed in a total volume of 20μL—including
10μL 2x SYBR Green PCR Master Mix (Applied Biosystems), 5μL of each primer at 5μM
concentration, and 1μL of the previously reverse-transcribed cDNA template. The PCR
primer sequence for adiponectin and GAPDH was chosen based on the sequences available
in GenBank (www.ncbi.nlm.nih.gov/Genbank). Melting curves were used to determine the
specificity of the gene products, which was subsequently confirmed by running the PCR
products on agarose gels. The threshold cycle (CT) value for each reaction, reflecting the
amount of PCR needed to identify a target gene was calculated. Specimens were run in
duplicate and the CT values averaged. GAPDH was used as internal control housekeeping
gene to normalize the PCRs for the amount of RNA added to the reverse transcription
reactions. The data was analyzed using the 2−ΔΔCT method [18] where ΔΔCT =
(CTadiponectin−CTGAPDH)omentum − (CTadiponectin−CTGAPDH)subcutaneous that allows to
determine the fold change in the target gene in the omentum compared to subcutaneous fat
from the same subject.
A fasting blood sample was also obtained from each subjects immediately before the
induction of general anesthesia and immediately spun in a refrigerated (4°C) centrifuge at
3,000 rpm for 10 minutes. The extracted plasma was used for glucose and insulin level
determinations. Plasma glucose concentration was determined by the glucose oxidase
method. Immunoreactive insulin was determined in plasma with a double-antibody system.
Insulin resistance was assessed by the homeostatic model assessment (HOMA): [fasting
plasma glucose (mmol/l) × fasting insulin (μU/ml)/22.5]. The extracted plasma was used for
adiponectin determinations by high-sensitivity enzymatic assay (Millipore, Inc.).
Cryopreserved human subcutaneous adipose stem cells (hASCs) purchased from Zen-Bio,
(Zen-Bio Inc., RTP, NC) were maintained and differentiated according to the supplier’s
specifications. Differentiated adipocytes maintained in AM-1 medium (Zen- Bio Inc., RTP,
NC) were exposed for 24 hours to 5, 10 and 100 ng/ml of des-(1–3)-IGF-I (des-IGF-I)
(Diagnostic System Laboratories), then harvested by Trizol reagent (Invitrogen Corp.,
Carlsbad, CA).
Statistical Analysis
Comparisons of continuous variables between the groups were completed by unpaired
Student’s t tests. Categorical variables were compared using the chi-square test or Fisher’s
exact test. Time course experiments were analyzed by ANOVA. The SPSS statistical
software program (version 17.0, SPSS, Chicago, USA) was used for all analyses. All tests
were 2-tail. P values of less than 0.05 were considered to indicate statistical significance.
RESULTS
Abdominal adipose tissues and plasma were obtained from 25 subjects undergoing GB
surgery, 15 non-obese subjects, and 12 subjects after gastric bypass at the average follow-up
of 19 months after the procedure.
As shown in Table 1, the three groups showed no significant differences in terms of age,
gender and racial distribution. The post-GB group had a mean BMI significantly higher
(P<0.01) than the non-obese control group but significantly lower than the obese group
(P<0.001). The demographics, postoperative weight loss and comorbidities resolution
observed in the post-GB cohort are similar to those observed in the general population of
post-GB patients followed in our practice.
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The differential adiponectin gene expression in the two adipose tissues was significantly
different among the three groups. As shown in the Figure1, omental adiponectin gene
expression was 5-fold higher in morbidly obese subjects after GB surgery when compared
with matched morbidly obese subjects and non-obese controls (P<0.01). The difference in
omental adiponectin gene expression observed in subjects after GB surgery and matched
non-obese control was not statistically significant.
The parameters relative to the glucose metabolism and circulating adiponectin of the three
groups are shown in Table 2. Subjects status post-GB and non-obese controls had similar
levels of plasma glucose and insulin levels. Consequentially, the insulin sensitivity
calculated as HOMA index in these groups was analogous. As expected, obese individuals
undergoing GB surgery had significant insulin resistance as demonstrated by their higher
HOMA indexes (P<0.001 vs. non-obese and post-GB groups). Circulating adiponectin levels
were significantly higher (p<0.05) in the obese group than non-obese and post-GB groups.
For the entire cohort of subjects, there was a significant negative correlation between
omental adiponectin expression and insulin resistance expressed by HOMA-IR values (r=
−0.62, P<0.001).
To investigate temporal regulation of adiponectin mRNA expression during adipogenesis,
human ASCs were differentiated into mature adipocyte over a 13 days period. As shown in
Figure 2A, adiponectin expression was significantly increased during adipogenesis (p<0.05)
reaching the highest level at day 13 (mature adipocyte status). To define the role of
inflammation cytokines on adiponectin expression, adipocytes were incubated with 12.5 ng/
ml of TNFα. As shown in Figure 2B, TNFα significantly decreased (P<0.05) adiponectin
expression in adipocytes, in a time-course fashion.
DISCUSSION
In the current study, adiponectin gene expression was determined in plasma, subcutaneous
and omental adipose tissues of individuals after GB surgery and compared with age matched
obese and non-obese individuals. The results of our study data clearly indicate that
adiponectin mRNA expression is selectively up-regulated in the omental adipose tissue of
subject after significant weight loss induced by GB surgery. The levels of adiponectin gene
expression in the omentum are significantly higher than the one observed in age matched
obese subjects and similar to those observed in non-obese matched subjects. This is a very
important finding because adiponectin is the most abundant adipose tissue secretory protein
and has a mechanistic role in the pathogenesis of insulin resistance and atherosclerosis [11,
15]. In fact, adiponectin has insulin-sensitizing effects and inhibits expression of key
atherosclerotic proteins and actions such as TNF-α [19]. Therefore, the selective up-
regulation of adiponectin in the omental fat depot might be one of the main cause for the
improved glucose metabolism [20] and reduced CVD risk [21] observed in patients who
underwent GB surgery. A previous study has demonstrated that the negative correlation of
adiponectin levels and visceral adiposity is stronger than between adiponectin levels and
subcutaneous adiposity [22]. However in their paper they were unable to identify the
mechanism by which plasma levels were reduced in individuals with visceral fat
accumulation. Our data clarify that decreased expression in the omental fat of obese
individual is responsible for such a change.
Previous studies have shown that plasma adiponectin levels are negatively associated with
the insulin-resistant state irrespective of gender or ethnicity [23] and significant reduction of
fat mass following bariatric surgery is associated with increased plasma adiponectin
concentrations [17, 24, 25]. Changes in adiponectin gene expression are mostly related to
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size and differentiation status of adypocytes. In obese individual adypocytes are large and
not well differentiated. These cell produce lower level of adiponectin and higher levels of
PAI-1 and TNFα. After significant weight loss adypocytes became smaller and well
differentiated. This new status is characterized by high level of adiponection and low levels
of inflammatory adipokines [26]. Circulating levels of adiponectin are direct expression of
the adipose tissue expression because this protein is secreted exclusively by mature
adipocytes [19]. However, there are no studies aimed to evaluate which adipose tissue depot
is the major contributor to the increased levels of circulating adiponectin observed after GB
surgery. In studies involving medical weight loss intervention, adiponectin adipose tissue
gene expression either increased [27] or did not change [28–30]. However in all these
studies, the resulting weight loss was less than 15% of body weight. A recent study from
Coughlin CC et al [31] was the first to examine the effect of weight loss induced by bariatric
surgery on adiponectin transcription in the adipose tissue. However, differently from our
study adiponectin gene expression was determined only in the subcutaneous fat that is not
the one linked to the metabolic syndrome [19]. Their data show that marked weight loss
induced by GB surgery increases adiponectin gene expression in both upper- and lower-
body subcutaneous fat. This increase in adipose tissue adiponectin production resulted in an
increase in plasma adiponectin concentrations, which likely contributed to the decrease in
insulin resistance observed after weight loss. Our study now clarifies that the omental fat
contributes more than the subcutaneous fat to the circulating levels of adiponectin. However
because our study was not designed to gather data about compartmental distribution of fat in
the obese groups, a potential difference between the groups in central adiposity may have
affected adiponectin levels.
An equally intriguing finding was that our results demonstrate statistically significant
negative correlations between omental adiponectin and insulin sensitivity as estimated by
the HOMA index. Previous studies [32, 33] have shown negative correlations between
circulating adiponectin and insulin resistance. However, our study is the first to demonstrate
that the adiponectin produced in the omental adipose tissue is the major contributor to this
correlation. This finding is consistent with the data recently presented by Lin et al [17].
These authors have shown that 6 months after GB surgery, decreases in visceral fat
measured by computed tomography were more strongly related to increases in adiponectin
and decreases in CRP than were changes in general adiposity or subcutaneous adipose
tissue.
In summary, omental adiponectin gene expression significantly increase after GB surgery
reaching levels equal to age and gender matched non-obese control subjects. Omental
adiponectin expression has a significant negative correlation with insulin sensitivity status.
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Relative Adiponectin RNA levels normalized to GAPDH RNA levels in subcutaneous and
omental adipose tissue collected from obese patients, patients at least 12 months after
RYGB, and non-obese controls. Data presented as mean ± SEM.; * = P<0.01 vs. non-obese
control and post-GB.
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A. Adiponectin mRNA levels during adipogenesis. B. Time-course effect of TNFα on
adiponectin mRNA expression in cultured adipocytes. Data presented as mean ± SEM.
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Table 1








Gender (M/F) 6/9 1/11 6/19
Age (years) 46 ± 12 43 ± 12 43 ± 9
BMI (kg/m2) 24.5 ± 2.7 29.7 ± 5.1* 48.0 ± 11.3**
Race 13C, 2AA 11C, 1AA 22C, 2AA, 1H
Type II Diabetes 0/15 1/12 8/25
*
= P <0.01 vs. Non-obese Control and Obese
**
= P <0.001 vs. Non-obese Control and Post-RYGB
C=Caucasian; AA=African-American; H=Hispanic























Insulin (μIU/mL) 7.1 ± 1.9 7.2 ± 2.3 18.8 ± 6.2*
Glucose (mmol/L) 4.8 ± 0.4 5.1 ± 0.5 6.4 ± 0.6*
HOMA 1.6 ± 0.3 1.7 ± 0.6 5.4 ± 1.7*
Adiponectin (μg/ml) 4.7 ± 2.7 4.8 ± 2.7 2.4. ± 1.4**
*
= P <0.01 vs. Non-obese Control and Post-RYGB
**
= P <0.05 vs. Non-obese Control and Post-RYGB
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